ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Natco Pharma's board has approved a Rights Issue to raise ₹1,279.36 Crore. The company will issue 17,058,082 equity shares at ₹750 each in a 2:21 ratio.
Natco Pharma's board approved a Rights Issue of 1,70,58,082 shares aggregating to ₹1,279.36 Crore. The issue is priced at ₹750 per share with a 2:21 ratio.
Natco Pharma will hold a board meeting on 25th September 2026 to finalise terms for its previously approved rights issue, including pricing and record date.
Natco Pharma has received in-principle approval from BSE and NSE for its upcoming Rights Issue of fully paid-up equity shares.
Natco Pharma proposes a Rights Issue of equity shares aggregating up to ₹1,300 Crore. The company has filed the Draft Letter of Offer for this capital raise.
Natco Pharma board approved a rights issue of up to ₹1,300 crore face value ₹2 equity shares. The demerger scheme will be revised post-completion of the raise.
Natco Pharma Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26.
Natco Pharma issued the notice for its 43rd Annual General Meeting to be held on September 30, 2026, covering agenda items including director appointment and fund-raising.
Natco Pharma filed its Annual Report for FY 2025-26 as required under SEBI regulations. The 43rd AGM is scheduled for September 30, 2026.
Natco Pharma Limited has scheduled a board meeting for September 9, 2026, to discuss potential fund-raising proposals.